This press release from Boston Scientific Corporation details their strong financial performance for the second quarter of 2025, significantly exceeding their own guidance for both net sales and earnings per share. The report highlights impressive growth across various segments and regions, with particularly notable increases in Cardiovascular sales and the United States market. Furthermore, the company discusses recent strategic achievements, including FDA and CE mark approvals for innovative medical devices and the completion of key acquisitions, all contributing to their positive outlook for the remainder of 2025. The document also includes detailed financial statements and reconciliations of non-GAAP measures to provide a comprehensive overview of their financial health.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana